HUTCHMED (CHINA) LS-1
Research HUTCHMED (CHINA) LS-1 (H7T2) on Bullrun: market cap EUR 1.71B, P/E 98.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerH7T2
- ExchangeF
- CountryHong Kong
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.71B
- P/E98.5
- Financial periodFY2025
- RevenueUSD 548.51M
- Revenue growth-13.0%
- Net incomeUSD 456.91M
- Free cash flow-USD 88.81M
- Gross margin38.7%
Valuation Snapshot
latest market cap is EUR 1.71B; P/E is 98.5.
Peer valuation comparison
Latest P/E is 98.5x versus a Healthcare sector median of 24.46x (302.7% above).
Latest P/E is 98.5x versus a Hong Kong median of 10.75x (816.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 548.51M | USD 456.91M | -USD 88.81M | 38.7% | 0.53 | USD 71.33M | USD 97.89M | USD 1.24B |
| FY2024 | USD 630.20M | USD 37.73M | -USD 17.44M | 44.6% | 0.04 | USD 153.96M | USD 89.82M | USD 759.93M |
| FY2023 | USD 838.00M | USD 100.78M | USD 186.65M | 54.1% | 0.12 | USD 283.59M | USD 86.13M | USD 730.54M |
| FY2022 | USD 426.41M | -USD 360.84M | -USD 305.26M | 27.0% | -0.43 | USD 313.28M | USD 27.01M | USD 610.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 1.71B | 98.5 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About HUTCHMED (CHINA) LS-1
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HUTCHMED (CHINA) LS-1's market cap?
HUTCHMED (CHINA) LS-1's market capitalization is EUR 1.71B.
What is HUTCHMED (CHINA) LS-1's P/E ratio?
HUTCHMED (CHINA) LS-1's price-to-earnings (P/E) ratio is 98.5.
What does HUTCHMED (CHINA) LS-1 do?
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.